# Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure

> **NCT03821701** · NA · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 340 (estimated)

## Conditions studied

- Chronic Heart Failure

## Interventions

- **DRUG:** Entresto
- **DRUG:** ACEI/ARB

## Key facts

- **NCT ID:** NCT03821701
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-01
- **Primary completion:** 2021-01-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2019-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03821701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03821701, "Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03821701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*